4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

Quick Answer: Disulfiram (Antabuse) is an aversive agent that irreversibly inhibits aldehyde dehydrogenase (ALDH-2), causing a toxic accumulation of acetaldehyde upon ethanol ingestion. The resulting Disulfiram-Ethanol Reaction (DER) triggers flushing, throbbing headache, violent vomiting, hypotension, tachycardia, and potential cardiovascular collapse. Disulfiram requires 12–24 hours of abstinence prior to initiation, and sensitivity persists for up to 14 days after stopping. Because unsupervised adherence is poor, disulfiram requires Directly Observed Therapy (DOT). Prominent off-label second-line MAUDs include: Topiramate (200–300 mg/day; AMPA/kainate antagonist and GABA enhancer; causes cognitive slowing, paresthesias, and kidney stones); Gabapentin (900–1,800 mg/day; $\alpha_2\delta$ calcium channel ligand; ideal for sleep and anxiety, 100% renal clearance); and Baclofen ($GABA_B$ agonist; safe and efficacious in advanced alcoholic cirrhosis).

---

1. Disulfiram (Antabuse): Aversive Pharmacotherapy

Disulfiram operates through a psychological deterrent mechanism (aversive conditioning) rather than altering craving pathways in the central reward circuitry.

Biochemical Mechanism & The Acetaldehyde Cascade

Normal ethanol metabolism proceeds in the liver via a two-step enzymatic oxidation:

$\text{Ethanol} \xrightarrow{\text{Alcohol Dehydrogenase (ADH)}} \text{Acetaldehyde} \xrightarrow{\text{Aldehyde Dehydrogenase (ALDH-2)}} \text{Acetate}$

Disulfiram and its active metabolites (diethyldithiocarbamate and carbon disulfide) irreversibly inhibit hepatic aldehyde dehydrogenase (specifically the mitochondrial ALDH-2 isoenzyme) via carbamylation of active-site cysteine residues:

• Acetaldehyde Accumulation: When alcohol is consumed while ALDH-2 is inhibited, the oxidation of acetaldehyde to acetate is blocked, causing acetaldehyde concentrations in the blood and tissues to surge 5- to 10-fold higher than concentrations observed during normal alcohol metabolism.
• Vascular & Autonomic Toxicity: Acetaldehyde stimulates massive histamine release, induces direct vascular endothelial vasodilation, causes catecholamine discharge from adrenal stores followed by peripheral catecholamine depletion, and inhibits myocardial contractility.

[Ingestion of Ethanol]
       │
       ▼ (Alcohol Dehydrogenase)
[Toxic Acetaldehyde Surge (5-10x Normal)] ───X (ALDH-2 Irreversibly Inhibited by Disulfiram)
       │
       ▼ (Massive Histamine & Catecholamine Release, Severe Vasodilation)
[THE DISULFIRAM-ETHANOL REACTION (DER)]
       │
       ├─ Facial Flushing, Throbbing Cephalalgia, Diaphoresis
       ├─ Intractable Nausea, Violent Emesis, Hyperventilation
       └─ Severe Hypotension, Tachycardia, Shock & Cardiac Arrhythmias

The Disulfiram-Ethanol Reaction (DER)

The clinical syndrome of a DER is rapid and potentially lethal:

• Onset & Duration: Symptoms emerge within 5 to 15 minutes of ethanol ingestion, peaking at 30 to 60 minutes and persisting for several hours (or as long as ethanol remains in circulation).
• Mild to Moderate DER: Intense cutaneous flushing of the face and upper chest, conjunctival injection, severe throbbing headache ("pounding temples"), profuse diaphoresis, dyspnea, hyperventilation, chest tightness, palpitations, tachycardia, nausea, intractable vomiting, weakness, and vertigo.
• Severe & Fatal DER: Marked systemic vasodilation, precipitous hypotension, circulatory shock, ST-segment depression, myocardial infarction, life-threatening ventricular arrhythmias, acute congestive heart failure, pulmonary edema, convulsions, altered consciousness, and death.
• Medical Management of Severe DER:
  • Immediate transfer to an emergency department or intensive care setting.
  • Continuous cardiac monitoring, pulse oximetry, and frequent blood pressure checks.
  • Fluid Resuscitation: Aggressive IV crystalloid infusions to restore intravascular volume and combat vasodilation.
  • Vasopressor Selection (CRITICAL): If vasopressors are required for refractory shock, norepinephrine or phenylephrine is the agent of choice. Avoid dopamine, because disulfiram also inhibits dopamine $\beta$-hydroxylase (the enzyme that converts dopamine to norepinephrine); dopamine is ineffective and can paradoxically worsen hypotension and arrhythmias.
  • High-dose IV ascorbic acid (vitamin C) and parenteral antihistamines ($H_1$ and $H_2$ blockers) are standard supportive adjuncts.

Prescribing Parameters, Rules & Patient Education

• Standard Dosing: 250 mg orally once daily (typical maintenance range: 125 mg to 500 mg daily). Historical practices utilizing high loading doses of 500 mg daily for two weeks are generally replaced by direct initiation of 250 mg daily.
• The 12- to 24-Hour Sobriety Rule: Disulfiram must never be initiated until the patient has achieved complete abstinence from alcohol for at least 12 to 24 hours. The clinician must document a clinical blood alcohol concentration (BAC) of 0.000 g/dL prior to the initial dose.
• The 14-Day Post-Discontinuation Rule: Because disulfiram causes irreversible enzyme inhibition, recovery of baseline ALDH activity requires de novo synthesis of new enzyme protein by hepatocytes. Consequently, a severe DER can occur if alcohol is ingested up to 14 days (2 weeks) after the last dose of disulfiram.
• Hidden Dietary & Environmental Ethanol Sources: Patients must be educated with an exhaustive list of hidden alcohol sources:
  • Culinary: cooking wines, wine vinegars, sherry-infused gravies, bourbon sauces, flambé desserts, baked goods containing real vanilla or almond extracts, fermented beverages (kombucha, non-alcoholic "near-beers" containing 0.5% ABV).
  • Medicinal: liquid cough and cold elixirs, tinctures, alcohol-containing mouthwashes (e.g., standard Listerine).
  • Topical / Occupational: alcohol-based hand rubs, aftershaves, colognes, perfumes, rubbing alcohol (isopropanol/ethanol), industrial solvents, paint thinners, and varnishes (inhalation of high vapor concentrations can trigger a DER).

Contraindications & Toxicity Monitoring

[!IMPORTANT] The Evidence-Based Imperative for Directly Observed Therapy (DOT): Multiple large randomized clinical trials (most notably the landmark Fuller et al. VA cooperative study) demonstrated that unsupervised disulfiram is no more effective than placebo in maintaining abstinence. Because disulfiram does not reduce craving, non-adherent patients simply skip their daily dose for 2 to 3 days when the urge to drink strikes. Disulfiram is clinically effective only when administered under Directly Observed Therapy (DOT), where ingestion is witnessed daily by a committed spouse, family member, clinic nurse, or formal monitoring program.

---

2. Topiramate: Off-Label Glutamate & GABA Modulator

Topiramate (Topamax) is an anticonvulsant that possesses a multifaceted neurochemical profile uniquely suited to treating Alcohol Use Disorder.

Pharmacodynamic Mechanisms

1. AMPA/Kainate Glutamate Antagonism: Topiramate selectively antagonizes post-synaptic AMPA ($\alpha$-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and kainate glutamate receptors, suppressing excitatory glutamatergic neurotransmission.
2. GABA Facilitation: It acts as a positive allosteric modulator at non-benzodiazepine binding sites on GABA-A receptors, enhancing inhibitory chloride currents.
3. Mesolimbic Dopamine Suppression: Through dual glutamatergic suppression and GABA enhancement in the VTA, topiramate blunts ethanol-induced dopamine release in the nucleus accumbens, extinguishing both craving and reward.
4. Carbonic Anhydrase Inhibition: Weakly inhibits carbonic anhydrase (isozymes CA-II and CA-IV), driving specific clinical side effects.

Clinical Prescribing & Slow Titration Protocol

• Major Advantage: Unlike disulfiram or acamprosate, topiramate does not require pre-existing abstinence; it can be safely initiated while the patient is still actively drinking, making it an outstanding harm-reduction option.
• Target Maintenance Dose: 200 to 300 mg/day administered in two divided doses (e.g., 100–150 mg PO BID).
• Mandatory "Low and Slow" Titration Schedule: To minimize central neurocognitive side effects, titrate upward over a 6- to 8-week period:

Week 1: 25 mg PO once daily at bedtime
Week 2: 50 mg/day (25 mg in morning, 25 mg at bedtime)
Week 3: 75 mg/day (25 mg in morning, 50 mg at bedtime)
Week 4: 100 mg/day (50 mg in morning, 50 mg at bedtime)
Weeks 5-8: Increase by 50 mg/day weekly until target of 200 to 300 mg/day is reached

Adverse Effect Profile & Monitoring

• Cognitive Dulling ("Dopamax"): Impaired concentration, psychomotor slowing, word-finding difficulty (anomia), and memory impairment. This is the primary reason for treatment discontinuation. Slow titration markedly mitigates this risk.
• Paresthesias: Tingling sensation in fingers, toes, and perioral region (occurs in up to 50% of patients due to carbonic anhydrase inhibition). Reassure the patient that it is benign and non-neuropathic.
• Nephrolithiasis (Kidney Stones): Carbonic anhydrase inhibition causes renal tubular alkalinization and hypocitraturia, precipitating calcium phosphate stones. Instruct patients to maintain liberal hydration (2 to 3 liters of fluid daily).
• Non-Anion Gap Metabolic Acidosis: Due to renal bicarbonate wasting. Monitor baseline and periodic serum bicarbonate ($HCO_3^-$) levels.
• Weight Loss / Anorexia: Induces satiety; beneficial in patients with metabolic syndrome or obesity, but requires caution in cachectic individuals.
• Ocular Warning: Rarely causes secondary angle-closure glaucoma and acute myopia (discontinue immediately if acute eye pain or visual blurring occurs).

---

3. Gabapentin: Voltage-Gated Calcium Channel Modulation

Gabapentin (Neurontin) is an alkylated analogue of GABA that does not bind directly to GABA receptors or alter GABA uptake.

Pharmacodynamics & Clinical Utility

• Presynaptic Calcium Channel Blockade: Gabapentin binds with high affinity to the auxiliary $\alpha_2\delta-1$ subunit of presynaptic voltage-gated calcium channels (VGCC) in the neocortex, hippocampus, and amygdala. By blocking calcium influx into presynaptic terminals, it suppresses the exocytosis of excitatory neurotransmitters (glutamate, substance P, and norepinephrine).
• Clinical Niche in AUD: Highly efficacious in managing protracted withdrawal symptoms, including persistent insomnia, craving, generalized anxiety, and autonomic dysphoria.
• Target Dosing: 900 to 1,800 mg/day in divided doses (e.g., 300 mg TID up to 600 mg TID, with the largest fraction often given at bedtime to promote restorative sleep architecture).
• Hepatic & Renal Pharmacokinetics: Gabapentin undergoes zero hepatic metabolism and has zero protein binding; it is excreted 100% unchanged in urine. It is exceptionally safe in patients with severe hepatic disease or cirrhosis, but requires dose reduction in renal impairment.

Misuse, Diversion & Safety Warnings

• SUD Population Warning: Gabapentin produces mild sedative, dissociative, and anxiolytic effects at supratherapeutic doses, leading to significant misuse and diversion among individuals with substance use disorders.
• Lethal Synergism with Opioids / Sedatives: Concurrent ingestion with opioids, benzodiazepines, or alcohol causes profound, synergistic central nervous system and respiratory depression (FDA Safety Alert).
• Regulatory Status: Multiple states have reclassified gabapentin as a Schedule V controlled substance. Clinicians must routinely query the Prescription Drug Monitoring Program (PDMP) prior to prescribing.

---

4. Baclofen: Selective $GABA_B$ Agonism & The Cirrhosis Milestone

Baclofen (Lioresal) is a lipophilic structural analogue of GABA that acts as a stereospecific agonist at metabotropic $GABA_B$ receptors.

Pharmacology & Hepatic Safety in Cirrhosis

• Mechanism: Activation of Gi-protein-coupled $GABA_B$ receptors stimulates inwardly rectifying potassium channels and inhibits voltage-dependent calcium channels, hyperpolarizing neuronal membranes. In the mesolimbic system, this dampens VTA dopaminergic firing, blunting alcohol craving and conditioned reinforcement.
• Clinical Trial Evidence in Cirrhosis (The Addolorato Trial): In a landmark randomized controlled trial published in The Lancet (Addolorato et al., 2007), baclofen was evaluated in patients with severe Alcohol Use Disorder and advanced liver cirrhosis (Child-Pugh Class A, B, and C with jaundice or ascites):
  • 71% of patients receiving baclofen achieved continuous complete abstinence compared to 29% in the placebo group.
  • Marked, statistically significant decreases in serum transaminases, bilirubin, and GGT occurred.
  • Baclofen demonstrated zero hepatotoxicity and did not precipitate hepatic encephalopathy.
• Elimination: Approximately 70% to 80% is excreted renally unchanged, with minimal hepatic clearance (~15%).
• Dosing: Initiate at 5 mg PO TID for 3 days, titrate to 10 mg PO TID (30 mg/day), with further titration up to 60 to 80 mg/day in divided doses based on response.
• Discontinuation Warning: Never discontinue abruptly; abrupt cessation of baclofen can precipitate severe withdrawal characterized by hallucinations, delirium, hyperpyrexia, seizures, and rebound spasticity. Must be tapered gradually over 1 to 2 weeks.

---

5. Comprehensive Cross-Comparison of Second-Line MAUDs